Prognostic Importance of the Soluble Form of IL-2 Receptor^|^alpha; (sIL-2R^|^alpha;) and its Relationship with Surface Expression of IL-2R^|^alpha; (CD25) of Lymphoma Cells in Diffuse Large B-cell Lymphoma Treated with CHOP-like Regimen with or without Rituximab : A Retrospective Analysis of 338 Cases

Abstract

We evaluated the prognostic significance of the serum level of the soluble form of interleukin-2 receptorα (sIL-2Rα) and investigated its association with CD25 expression on tumor cells in diffuse large B-cell lymphoma (DLBCL). Three hundred and thirty-eight adult patients with newly diagnosed DLBCL were eligible for this retrospective study. 32.2% of patients were treated with CHOP-like regimen and 67.8% with R-CHOP-like regimen. CD25 expression on the surface of tumor cells was evaluated in 143 cases and its relationship with sIL-2Rα level was also investigated. Both overall survival (OS) and progression-free survival (PFS) were poorer in patients with higher sIL-2Rα, in both R-CHOP and CHOP groups. sIL-2Rα > 1,000 U/mL and performance status (PS) ≥ 2 were independently associated with poorer OS, and sIL-2Rα > 1,000 U/mL, age > 60 years, and ≥ 2 extranodal sites were independently associated with poorer PFS in the R-CHOP group. The sIL-2Rα level was higher in the CD25-positive group than in the CD25-negative group in stage 3 or 4 disease (p = 0.010). Multiple linear regression analysis showed CD25 expression to be independently correlated with sIL-2Rα levels. High sIL-2Rα is an important risk factor for survival in DLBCL treated with not only CHOP-like, but also R-CHOP-like regimens, regardless of the tumor's expression of CD25.

The emerging role of anti‐CD25 directed therapies as both immune modulators and targeted agents in cancer

“…Both (HL) and non-Hodgkin lymphoma (NHL) malignant cells have demonstrated expression of CD25 (Tesch et al, 1993;Waldmann, 2007). NHL tumours with high levels of surface CD25 expression include DLBCL (Hashimoto et al, 2013;Yoshida et al, 2013), follicular lymphoma (Yoshida et al, 2013) and peripheral T cell lymphoma including angioimmunoblastic T cell lymphoma and anaplastic large cell lymphoma (Gualco et al, 2009). Rarer diseases showing CD25 expression include Waldenstr€ om macroglobuliaemia (San Miguel et al, 2003) and systemic mastocytosis, which is defined by its CD25 expression (Lim et al, 2009).…”

Plasma Factors for the Differentiation of Hodgkin’s Lymphoma and Diffused Large B Cell Lymphoma and for Monitoring Remission

“…There are limited data on the use of these cytokines in confirming remission of DLBCL patients. sIL-2R is known to be a poor prognostic factor for DLBCL patients as enhanced levels of sIL-2R are associated with lower rates of event-free survival and overall survival [35][36][37]. It will need to be shown in future studies whether there is a causal relationship between remission and the decreased sIL-2R concentration.…”